
AAPG Stock Forecast & Price Target
AAPG Analyst Ratings
Bulls say
Ascentage Pharma Group is positioned favorably because its two de-risked commercial anchors, olverembatinib and lisaftoclax, now have broad China reimbursement support, with lisaftoclax added to the 2026 NRDL and both assets’ approved indications covered effective Jan 1, 2027. The company generated $41.6M in product sales in 1H26, while olverembatinib’s NRDL coverage helped drive FY25 revenue of $62.2M, up 81% YoY, underscoring the commercial leverage from reimbursement and hospital formulary expansion. Its outlook is further strengthened by a differentiated apoptosis platform, seven pipeline drug candidates, and multiple catalysts through 2H27, including enrollment completions, ASH data, and potential NDA filings, with cash of $279.4M supporting runway into 2028.
Bears say
Ascentage Pharma Group is viewed negatively because its lead assets appear to face weak differentiation and execution risk: slower adoption in China limits Olverembatinib growth, global studies have not clearly separated it from incumbents, and Lisaftoclax has faced enrollment or regulatory delays that push back commercialization. The company’s Bcl-2 strategy also looks challenged by evidence that venetoclax improved response rates but not overall survival in the registrational Phase 3 VERONA study, while Lisaftoclax’s pharmacokinetic and tolerability advantages may not materially improve dose intensity, treatment duration, or survival. In addition, APG-3288 enters a crowded BTK degrader field with a high safety bar, and the cited sonrotoclax data show substantial hematologic toxicity, infections, dose reductions, and even treatment-emergent deaths, all of which could constrain uptake, pricing power, and investor confidence.
This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ascentage Pharma Group International (AAPG) Forecast
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares